Weixin Kang's Amino Acid Injection (20AA) is approved for marketing!

Recently, Inner Mongolia Baiyi Pharmaceutical Co., Ltd. , a wholly-owned subsidiary of Weixin Kang, received the "Certificate of Drug Registration" (Drug Approval No.: GYZZ H20223734) for Compound Amino Acid Injection (20AA), which was approved and issued by the State Drug Administration. The company has already started the pre-production preparation work and the launch of this product will bring new treatment options for patients.

Compound Amino Acid Injection (20AA) is a compound formulation of various amino acids, containing 20 amino acids, for patients with severe hepatic insufficiency and imminent or developed hepatic encephalopathy, to provide amino acids for parenteral nutrition and to meet their metabolic needs. Compound Amino Acid Injection (20AA) is a drug in the National Health Insurance List (Category B). The original product is Aminoplasmal® Hepa-10%, which was launched in Germany in June 1987 by B. Braun Melsungen AG (Belang, Germany).

Compound Amino Acid Injection (20AA)

The main amino acid formulations for liver disease currently in clinical use include Compound Amino Acid (3AA), Compound Amino Acid (6AA), Compound Amino Acid(15AA), Compound Amino Acid (17AA-III), Compound Amino Acid Hexa, Compound Amino Acid / Compound Amino Acid(20AA).

Compound Amino Acid Injection (20AA) has chosen a special production process, and according to the relevant national policies, the obtaining of the Drug Registration Certificate is regarded as passing the consistency evaluation. Weixin Kang's product Weixin Lemon is the first generic drug in Compound Amino Acid Injection (20AA) to pass the consistency evaluation.

Over the years, Weixin Kang has been upholding the mission of "Good health and well being", continuously improving its innovation and technology, striving to provide more innovative and accessible treatment solutions, and continuously contributing to the construction of a healthy China!